Clinical Trials Browser

Neoplasms × atezolizumab × 1 year × Clear all

NCT03148418 2026-04-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT05862285 2026-04-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

Neoplasms

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

NCT07192926 2026-02-20

SARCO-CTI

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Phase 2 Active not recruiting

Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT05152472 2026-01-08

ATEZOGIST

Phase 2 Recruiting

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT06551142 2025-12-18

PanTumor-101

Phase 1 Recruiting

Neoplasms

NCT03755791 2025-12-11

COSMIC-312

Phase 3 Active not recruiting

837 enrolled 14 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT04196530 2025-11-12

EIK1001

Phase 1 Completed

Neoplasms

NCT05394337 2025-10-09

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1/2 Recruiting

Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT04477759 2025-07-15

DEHART

Phase 1 Completed

18 enrolled 12 charts

Head and Neck Neoplasms, Neoplasms

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

NCT04602078 2025-04-24

AUREA

Phase 2 Completed

82 enrolled 20 charts

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms